Research Analysts Issue Forecasts for BriaCell Therapeutics Corp.’s FY2029 Earnings (NASDAQ:BCTX)

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Equities researchers at HC Wainwright issued their FY2029 EPS estimates for shares of BriaCell Therapeutics in a report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.05) per share for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($1.39) per share.

BriaCell Therapeutics Stock Performance

Shares of BCTX stock opened at $0.65 on Friday. The stock’s 50-day simple moving average is $0.70 and its 200-day simple moving average is $1.55. The firm has a market capitalization of $11.87 million, a PE ratio of -0.52 and a beta of 1.31. BriaCell Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $6.36.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC increased its holdings in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 50,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Onyx Bridge Wealth Group LLC owned approximately 0.31% of BriaCell Therapeutics worth $143,000 as of its most recent SEC filing. 15.42% of the stock is currently owned by institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.